Evaluation of atorvastatine effect in reduction of negative symptoms in inpatients with schizophrenia disorder

Evaluation of atorvastatine -as an adjuant- in reduction of negative symptoms in schizophrenic inpatients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202067290N1

Enrollment

Registered

2012-03-22

Start date

2011-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophernia. Schizophrenia

Interventions

Intervention 1: Intervention group: 6 mg risperidon + Atorvastatin 20 mg, daily. Intervention 2: Control group: 6 mg risperidon + Palacebo, daily.

Treatment - Drugs

Placebo

Intervention group: 6 mg risperidon + Atorvastatin 20 mg, daily

Control group: 6 mg risperidon + Palacebo, daily

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a diagnosis of schizophrenia according to DSM-IV-TR; an overall score of 50 or higher on the PANSS scale; 15 or higher negative score in PANSS scale; age range between 70-18 years; duration of at least 1 year from onset of the illness. Exclusion criteria: history of sensitivity to statins; active liver disease or inexcusable stable increase in liver enzymes ; renal failure; serious medical illness; substance abuse or dependency in recent months; pregnancy; lactation; other simultaneous psychiatric disorders requiring medication; desire to homicide or suicide; having dementia and severe cognitive impairments not bound to schizophrenia; organic brain disorders such as seizure; severe mental retardation and Parkinsonism; consumption of oral antipsychotics during last month or long-acting Injectable forms within three months; Concomitant use of other drugs such as antidepressants; lithium which may interfere in treatment; drug-resistant schizophrenia disorder;, lack of response to appropriate dosage and duration of Risperidone.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Negative sign. Timepoint: at the end of weeks 1 ,3 ,4 and 6. Method of measurement: PANSS questionnaire.	—

Secondary

Measure	Time frame
Positive sign. Timepoint: at the end of weeks 1 ,3 ,4 and 6. Method of measurement: PANSS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Ashrafpoori

Jundishapur University of Medical Sciences

ashrafpoori@gmail.com+98 61 1374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026